ERIC | Ongoing Research Projects
ERIC is currently carrying on several translational and clinical research projects in CLL. Every member is welcome to participate to any of them by contacting the coordinator of the project of interest. Every member should also feel welcome to propose a new project by simply submitting at any time during the year a one-page application (
application form) to the ERIC board, describing the scientific rationale and the objectives of the study.
TRANSLATIONAL PROJECTS
Immunoglobulin Gene Sequences
-
CLL with double productive IGHV-IGHD-IGHJ rearrangements / Biclonal
P. Ghia, Milan/Italy and K. Stamatopoulos, Thessaloniki/Greece
» more -
Toward standardization of IG gene analysis in CLL: survey and quality control
contact person F. Davì Paris/France
» more
TP53 Gene Abnormalities
-
Recommendations for TP53 mutational analysis
S. Pospisilova, Brno/Czech Republic, S. Stilgenbauer Ulm/Germany and T. Zenz, Heidelberg/Germany
» more -
P53 function project
A. Kater Amsterdam/The Netherlands, S. Stilgenbauer, Ulm/Germany
» more -
MDM2 SNP
T. Zenz and A. Benner, Heidelberg/Germany
» more -
Indolent CLL with a deletion of 17p
D. Oscier, Bournemouth/UK
» more -
Metaanalysis p53 mutation in prospective trials
S. Stilgenbauer, Ulm/Germany, D. Gonzales, London/UK and T. Zenz, Heidelberg, Germany
» more
Flow Cytometry
-
ZAP70 harmonisation project
R Letestu and F. Cymbalista, Bobigny/France
» more -
The MRD harmonisation approach by flow cytometry
A. Rawstron, Leeds/UK
» more
Registries
-
International CLL registry for spontaneous regression in CLL: Proposal
I. Del Giudice, Roma/Italy
» more -
Online registry and support for Immunoglobulin gene sequence interpretation
K. Stamatopoulos, Thessaloniki/Greece and R. Rosenquist, Uppsala/Sweden
» more
CLINICAL PROJECTS
- Allogeneic hematopoietic cell transplantation in 17p-CLL in first or second complete or partial remission – a non-interventional prospective study
J. Schetelig, Dresden/Germany
» more - Long-term follow-up of clinical trials in CLL
B. Eichhorst, Cologne/Germany and P. Hillmen, Leeds/UK
» more - Erasmus TCRgd LGL study
A. Langerak, Rotterdam/The Netherlands
» more - Treatment of T-Prolymphocytic Leukemia with Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab - phase II trial
G. Hopfinger, Vienna/Austria
» more
- Phase IV Observational Study of Chronic Lymphocytic Leukemia (CLL) Patients Receiving Arzerra® (Ofatumumab)
C. Moreno, Barcelona/Spain and Colm Bradley, Houston/UK
Ofatumumab Trial eCRF (restricted website for ERIC members concerned with the Ofatumumab trial)
